A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib

Hamamoto, Takao; Kobayashi, Takashi; Taruya, Takayuki; Ishino, Takashi; Ueda, Tsutomu; Takeno, Sachio

doi:10.1016/j.anl.2020.10.005

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lenvatinib, an oral multitarget inhibitor, has been used in adjuvant therapy after thyroidectomy with neck dissection and postoperative chemoradiotherapy. Therapy extended the time to progression, but some AEs, like HT fatigue, anorexia and severe drug-induced hepatitis, forced investigators to taper the drug dose [ 144 , 145 ]. Results of treatment of ATC patients with lenvatinib (phase II trial) confirmed tumor size reduction (in more than half of evaluated patients), PR to treatment ( n = 1) and >30% reduction in the total size of the target lesion.…”

Section: Currently Used and Investigated Targeted Therapies In Tcsmentioning

confidence: 99%

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Ratajczak

Gawel

Godlewska

2021

IJMS

View full text Add to dashboard Cite

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are especially important. Ultrasonography examination followed by fine needle biopsy have become the gold standard for diagnosis of TCs, as these strategies allow for early-stage detection and aid accurate qualification for further procedures, including surgical treatment. Despite all the advancements in detection and treatment of TCs, constant mortality levels are still observed. Therefore, a novel generation line of targeted treatment strategies is being developed, including personalized therapies with kinase inhibitors. Recent molecular studies on TCs demonstrate that kinase inhibitor-based therapies might be considered as the most promising. In the past decade, new kinase inhibitors with different mechanisms of action have been reported and approved for clinical trials. This review presents an up-to-date picture of new approaches and challenges of inhibitor-based therapies in treatment of TCs, focusing on the latest findings reported over the past two years.

show abstract

Section: Currently Used and Investigated Targeted Therapies In Tcsmentioning

confidence: 99%

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Ratajczak

Gawel

Godlewska

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Even with active treatment, only a few patients can survive for a long time, and many patients die in a short time. 2 , 3 Generally, the median survival time from diagnosis to death is only 1–6 months. According to the TNM staging guidelines of the 8th edition of the American Joint Commission on Cancer (AJCC), all ATC patients were stage IV: the primary lesions in stage IVA were limited to the thyroid IV a = T1-T3b, N0/NX, M0); local lymph node involvement can be seen in IVA/IVB stage (IV B: T1-T3a, N1, M0 or T3b-T4, any N, M0); distant metastasis in IVC stage (IV C: any T, any N, M0) 4 the clinical manifestations of ATC are related to the rapidly growing neck mass.…”

Section: Introductionmentioning

confidence: 99%

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, and it is rapidly falling without any effective therapeutic options. Although radical surgery, radiotherapy, and chemotherapy are performed on patients, the curative effect is suboptimal, and the survival rate is still poor. The discovery of altered gene pathways involved in this aggressive disease has advanced, but molecular targeted drugs targeting these pathways are still in clinical trials. To date, there is no effective way to treat this disease, so it is particularly urgent to find new treatments. At present, multimodal therapy is gradually being applied in clinical practice, which provides a new possibility for prolonging the survival time and improving the prognosis of anaplastic thyroid carcinoma. In this study, we retrospectively analyzed the current clinical multimodal therapy for patients with anaplastic thyroid cancer to evaluate its effect on improving the survival of patients with anaplastic thyroid cancer at different stages.

show abstract

Lenvatinib

2022

Reactions Weekly

View full text Add to dashboard Cite

A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib

Cited by 3 publications

References 15 publications

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer

Lenvatinib

Contact Info

Product

Resources

About